Bioventus  logo
Bioventus BVS
$ 13.61 2.55%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Bioventus Cash Flow 2025-2011 | BVS

Brief cash flow overview of Bioventus

The comparison covers five available annual reports between 2021 and 2025.

Operating cash flow advanced from $23 million to $74.7 million. A +224.8% gain and 34.2% CAGR show rapidly improving cash generation.

Operating cash flow was above zero 4 times out of five. Most, but not all, periods generated cash.

Operating cash margin reached 13.1% versus 5.3% initially. Revenue converted into cash more effectively.

Receivables and inventory net of payables grew by $29.9 million, absorbing resources equal to about 5.3% of revenue.

Cash flow takeaway

Bioventus 's cash generation remains workable and supports the business, though some uses of cash limit flexibility.

Annual Cash Flow Bioventus

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

74.7 M 38.8 M 15.3 M -13.5 M 23 M 71.8 M 40.7 M - - - - - - - -

Depreciation & Amortization

47 M 49.6 M 57.4 M 55.4 M 34.9 M 28.6 M 30.3 M - - - - - - - -

Accounts Payables

10.9 M 23.7 M 23 M 36.7 M 16.9 M - - - - - - - - - -

Accounts Receivables

128 M 127 M 123 M 136 M 125 M - - - - - - - - - -

Total Inventories

82.2 M 92.5 M 91.3 M 84.8 M 61.7 M - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Bioventus

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

28.8 M 8.93 M - - -19.3 M - - -6 M - - 2.49 M - -18.8 M -18.1 M -21 M - 9.87 M -713 K -18 M - 46.4 M 25.5 M 17.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

22.2 M 11.2 M 1.4 M 1.44 M 11.9 M 2.06 M 2.06 M 11.8 M 2.32 M 2.29 M 16.5 M - 2.26 M 2.7 M 12.5 M - 23.2 M 14.7 M 7.18 M - 21.8 M 14.5 M 7.26 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

20.2 M 24 M 26.6 M 24.2 M 19.2 M 16.8 M 24.4 M 19.1 M 17.6 M 41.4 M 32.8 M 36.7 M 19.1 M 25.7 M 22.5 M 16.9 M 10.9 M 9.88 M 10.3 M 4.42 M 4.42 M 4.42 M 4.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

138 M 121 M 130 M 132 M 118 M 122 M 137 M 126 M 113 M 120 M 119 M 136 M 132 M 143 M 119 M 125 M 105 M 102 M 89.5 M 88.3 M 88.3 M 88.3 M 88.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

79.8 M 83.2 M 96.3 M 96.5 M 94 M 90 M 87.6 M 97 M 97.6 M 96.3 M 88 M 84.8 M 77 M 69.1 M 64.7 M 61.7 M 36.6 M 34 M 39.8 M 29.1 M 29.1 M 29.1 M 29.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Bioventus , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Diagnostics research sector

Issuer Price % 24h Market Cap Country
CareDx, Inc CareDx, Inc
CDNA
$ 54.31 0.32 % $ 2.89 B usaUSA
Celcuity Celcuity
CELC
$ 79.99 0.12 % $ 3.74 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.1 1.85 % $ 1.46 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 34.88 0.09 % $ 1.01 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 221.56 0.21 % $ 158 B usaUSA
DexCom DexCom
DXCM
$ 87.73 0.21 % $ 34.2 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 21.27 0.51 % $ 655 M usaUSA
Guardant Health Guardant Health
GH
$ 176.31 0.27 % $ 22.1 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 163.9 0.2 % $ 12.9 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 522.02 0.1 % $ 42 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 267.86 0.41 % $ 46 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.75 3.33 % $ 89.2 K usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 303.98 0.09 % $ 25.3 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 99.97 0.01 % $ 6.75 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 617.15 0.23 % $ 17.8 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 492.34 0.11 % $ 30.8 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 4.01 0.62 % $ 371 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 6.5 4.33 % $ 5.12 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.36 0.03 % $ 2.35 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 13.57 2.72 % $ 2.95 B usaUSA
Natera Natera
NTRA
$ 390.79 0.41 % $ 53.4 B usaUSA
Biomerica Biomerica
BMRA
$ 2.61 0.36 % $ 7.61 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.7 0.29 % $ 1.28 B usaUSA
RadNet RadNet
RDNT
$ 73.21 0.11 % $ 5.5 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 18.29 0.45 % $ 5.19 B usaUSA
Neuronetics Neuronetics
STIM
$ 2.88 0.21 % $ 190 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 7.01 0.68 % $ 2.52 B irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 158.47 0.93 % $ 9.48 B usaUSA
Biodesix Biodesix
BDSX
$ 29.29 4.05 % $ 221 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.25 2.99 % $ 31.4 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 420.57 0.52 % $ 25 B usaUSA
Exagen Exagen
XGN
$ 8.55 1.39 % $ 184 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.7 0.55 % $ 9.26 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 15.08 11.68 % $ 162 M chinaChina
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 13.45 0.88 % $ 457 M israelIsrael